The case for & against
Bull & Bear analysis
Bearish
VolitionRx Limited (NYSE: VNRX) is an innovative biotechnology company focusing on developing blood-based diagnostic tests for cancer and sepsis using its proprietary NuQ technology platform. The firm is operationally positioned in the booming diagnostics sector, with a particular emphasis on liquid biopsies, which are non-invasive methods of detecting diseases. VolitionRx aims to improve patient outcomes in both human and veterinary markets, capitalizing on the growing demand for accessible and reliable diagnostic solutions.
Bull says
- ↑Q1 2026 revenue jumped 300% YoY to $1M, driven by licensing deals
- ↑Addressable market for cancer and sepsis diagnostics ~ $25B supports scale
- ↑10+ partnership discussions with top diagnostic firms could accelerate commercialization
- ↑New CaptureSeq tech yields >99% ctDNA purity, boosting diagnostic accuracy
- ↑Strong balance sheet with $3.1M cash on hand and $1M non-dilutive funding
- ↑High product innovation factor and extensive market potential underpin upside
Bear says
- ↓Negative earnings yield and weak profitability metrics signal financial stress
- ↓Q1 operating costs rose to $6.3M, up from $5.8M, straining cash
- ↓Net cash used in operations surged to $5.3M vs $4.3M prior year
- ↓FDA approval delays (2-year horizon) could defer commercialization
- ↓Heavy reliance on licensing deals risks revenue if agreements fall through
- ↓Competitive market and regulatory hurdles may limit new test adoption
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-18-2026bullish
Transcript signals
Bull points
- We do believe we are very close to that first human licensing deal, given the very wide range of discussions, including a few at the very final stage. So I do expect to close the first, which will be a massive milestone for us, this quarter, which of course means this month or next, because the end of September is the end of the quarter.
- Of those 11 networks, multiple of them now have ordered two or three times. They're very much liking the adaptability of the tests and how well it works. So we're getting a lot of repeat orders in NewQ Discover and NewQ Nets.
- We appreciate your time given the busy earnings season. As stated on our last call, one of our key financial goals for 2025 is to be cash neutral on a full year basis, meaning income, including licensing receipts, matches expenditure on a cash basis.
Bear points
- So we will not be providing revenue guidance for 2025 at this point in time.
- Cash and cash equivalents at the end of the quarter totaled approximately $2.3 million compared to $3.3 million at the end of 2024.
Read full transcript analysis ›